NEW YORK (GenomeWeb) – AutoGenomics on Monday priced its planned initial public offering at between $11 and $13 per share, with anticipated net proceeds of up to $46.6 million. 

In an amended prospectus, the company said it plans to offer 3.75 million shares of its common stock in its IPO. It plans to list its shares on the Nasdaq Global Market under ticker symbol "AGMX." 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.